Sienna Biopharmaceuticals, Inc. (SNNAQ)

Market Cap	23.00 -99.0%
Revenue (ttm)	n/a
Net Income	-47.95M
EPS	-1.80
Shares Out	22.78M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Open	0.000001
Previous Close	n/a
Day's Range	0.000001 - 0.000001
52-Week Range	0.000001 - 0.0002
Beta	147.81
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Sienna Biopharmaceuticals

Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas. It develops therapies in immunology and inflammation that target select pathways in tissues, such as skin. The company’s lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of psoriasis and associated pruritus; and SNA-125, a topical dual Janus kinase 3 inhibitor that is in Phase I/II clinical trial...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 13
• Stock Exchange: OTCMKTS
• Ticker Symbol: SNNAQ

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 15, 2026

Data Sources Report a data error